ADVERSE REACTIONS

Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than with placebo in two placebo-controlled 24-week trials1

Adverse reactions with BEVESPI AEROSPHERE with a >=2% incidence and more common than with placebo in two placebo-controlled 24-week trials
 
 

All study treatments administered BID.

Long-term safety

  • In a 28-week, long-term safety extension trial, 893 subjects who completed Trial 1 or Trial 2 were treated for up to an additional 28 weeks for a total treatment period of up to 52 weeks with BEVESPI AEROSPHERE, glycopyrrolate 18 mcg, or formoterol fumarate 9.6 mcg administered twice daily1
  • The adverse reactions reported in the long-term safety trial were consistent with those observed in the 24-week, placebo-controlled trials

All study treatments administered BID.